Solid Biosciences Q2 EPS $(0.61) Beats $(0.67) Estimate
Portfolio Pulse from Benzinga Newsdesk
Solid Biosciences (NASDAQ:SLDB) reported a Q2 EPS of $(0.61), beating the analyst consensus estimate of $(0.67) by 8.96%. This represents a 51.2% improvement over the $(1.25) per share loss from the same period last year.
August 13, 2024 | 8:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Solid Biosciences reported a Q2 EPS of $(0.61), beating the analyst consensus estimate of $(0.67) by 8.96%. This is a significant improvement from the $(1.25) per share loss in the same period last year, indicating better financial performance.
The better-than-expected EPS and significant year-over-year improvement suggest positive financial performance, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100